Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Top Cited Papers
- 27 May 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 377 (9779), 1760-1769
- https://doi.org/10.1016/s0140-6736(11)60405-4
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Pirfenidone in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2009
- The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important differenceThorax, 2009
- Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2009
- Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosisEuropean Journal of Pharmacology, 2008
- Pirfenidone Modulates Airway Responsiveness, Inflammation, and Remodeling after Repeated ChallengeAmerican Journal of Respiratory Cell and Molecular Biology, 2006
- High-Dose Acetylcysteine in Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 2005
- A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 2004
- A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational levelEuropean Journal of Pharmacology, 2002
- Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shockEuropean Journal of Pharmacology, 2002
- Lung Fibrosis is Ameliorated by Pirfenidone Fed in Diet After the Second Dose In A Three-Dose Bleomycin-Hamster ModelExperimental Lung Research, 1998